Last reviewed · How we verify

Standard Dose Ibuprofen — Competitive Intelligence Brief

Standard Dose Ibuprofen (Standard Dose Ibuprofen) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Pain Management, Inflammation.

marketed Nonsteroidal anti-inflammatory drug (NSAID) COX-1, COX-2 Pain Management, Inflammation Small molecule Live · refreshed every 30 min

Target snapshot

Standard Dose Ibuprofen (Standard Dose Ibuprofen) — Ottawa Hospital Research Institute. Ibuprofen inhibits cyclooxygenase (COX) enzymes to reduce the production of prostaglandins, thereby decreasing inflammation, pain, and fever.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Standard Dose Ibuprofen TARGET Standard Dose Ibuprofen Ottawa Hospital Research Institute marketed Nonsteroidal anti-inflammatory drug (NSAID) COX-1, COX-2
Ibuprofen/acetaminophen Ibuprofen/acetaminophen Montefiore Medical Center marketed Analgesic/antipyretic combination (NSAID + non-NSAID analgesic) Cyclooxygenase (COX-1, COX-2) for ibuprofen; prostaglandin synthesis and central pain pathways for acetaminophen
EC Aspirin 325 EC Aspirin 325 POZEN marketed Antiplatelet agent / NSAID Cyclooxygenase (COX-1, COX-2)
naproxen sodium codein naproxen sodium codein Diskapi Yildirim Beyazit Education and Research Hospital marketed NSAID + opioid combination analgesic COX-1, COX-2, mu opioid receptor
NSAID (Aceclofenac) NSAID (Aceclofenac) Dong-A ST Co., Ltd. marketed NSAID (nonsteroidal anti-inflammatory drug) COX-1, COX-2
Dexketoprofen Trometamol + Paracetamol Dexketoprofen Trometamol + Paracetamol Yuzuncu Yil University marketed NSAID + analgesic combination COX-1, COX-2 (dexketoprofen); central prostaglandin synthesis and pain pathways (paracetamol)
Pranoprofen eye drops Pranoprofen eye drops Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1, COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

  1. Università degli Studi di Brescia · 4 drugs in this class
  2. Bausch & Lomb Incorporated · 4 drugs in this class
  3. Bayer · 3 drugs in this class
  4. Pfizer · 3 drugs in this class
  5. Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
  6. Organon and Co · 3 drugs in this class
  7. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
  8. Bezmialem Vakif University · 2 drugs in this class
  9. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
  10. Center For Excellence In Eye Care · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Standard Dose Ibuprofen — Competitive Intelligence Brief. https://druglandscape.com/ci/standard-dose-ibuprofen. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing